These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 1720482

  • 1. Serotonin and platelet activation during treatment with isradipine.
    Fetkovska N, Sebekova K, Fedelesova V, Dzurik R.
    J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S31-3. PubMed ID: 1720482
    [Abstract] [Full Text] [Related]

  • 2. Platelet-activating effect of low-density lipoprotein and its reversal by isradipine.
    Fetkovská N, Fedelesová V, Kozlovský M, Dzúrik R.
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):175S-177S. PubMed ID: 1827014
    [Abstract] [Full Text] [Related]

  • 3. [Inhibition of thrombocyte activity in atherogenesis and thrombogenesis using isradipine and other calcium antagonists].
    Fet'kovská N, Ulicná L, Jakubovská Z.
    Vnitr Lek; 1993 Apr; 39(4):326-33. PubMed ID: 8351859
    [Abstract] [Full Text] [Related]

  • 4. Effects of the calcium antagonist isradipine on 24-hour ambulatory blood pressure, platelet aggregation, and neutrophil oxygen free radicals in hypertension.
    Ding YA, Han CL, Chou TC, Lai WY, Shiao MF.
    J Cardiovasc Pharmacol; 1992 Apr; 19 Suppl 3():S32-7. PubMed ID: 1376832
    [Abstract] [Full Text] [Related]

  • 5. Treatment of hypertension with dihydropyridine calcium antagonists and aspirin.
    Tison P, Ulicna L, Jakubovska Z, Oravcova J, Fetkovska N.
    Blood Press Suppl; 1994 Apr; 1():57-60. PubMed ID: 8205303
    [Abstract] [Full Text] [Related]

  • 6. Platelet activation by low-density lipoprotein and serotonin: effects of calcium antagonists.
    Fetkovska N.
    J Cardiovasc Pharmacol; 1992 Apr; 19 Suppl 3():S25-8. PubMed ID: 1376830
    [Abstract] [Full Text] [Related]

  • 7. Isradipine increases platelet--low-density lipoprotein binding: evidence from ex-vivo studies in humans.
    Schmid P, Pirich C, Fitscha P, Pesau B, Virgolini I, Sinzinger H.
    Blood Press Suppl; 1994 Apr; 1():65-9. PubMed ID: 8205305
    [Abstract] [Full Text] [Related]

  • 8. Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus.
    Klauser R, Speiser P, Gisinger C, Schernthaner G, Prager R.
    J Cardiovasc Pharmacol; 1990 Apr; 15 Suppl 1():S93-6. PubMed ID: 1695314
    [Abstract] [Full Text] [Related]

  • 9. Isradipine improves platelet function in hypertensives.
    Sinzinger H, Virgolini I, Rauscha F, Fitscha P, O'Grady J.
    Eur J Clin Pharmacol; 1992 Apr; 42(1):43-6. PubMed ID: 1531796
    [Abstract] [Full Text] [Related]

  • 10. Metabolic, hematological, and cardiac effects of long-term isradipine treatment in mild-to-moderate essential hypertension.
    Meriç M, Gören T, Atilgan D, Eren N, Cubukçu A, Koylan N.
    J Cardiovasc Pharmacol; 1992 Apr; 19 Suppl 3():S58-60. PubMed ID: 1376837
    [Abstract] [Full Text] [Related]

  • 11. Serotonin metabolism and platelet aggregation under antihypertensive treatment with nitrendipine.
    Sebeková K, Raucinová M, Sedláková K, Dzúrik R.
    J Cardiovasc Pharmacol; 1988 Apr; 12 Suppl 4():S161-3. PubMed ID: 2468865
    [Abstract] [Full Text] [Related]

  • 12. Carmoxirole inhibits platelet aggregation in vitro and ex vivo.
    Kirsten R, Breidert M, Sparwasser K, Ochs JG, Hesse K, Nelson K.
    Int J Clin Pharmacol Ther; 1995 Feb; 33(2):76-80. PubMed ID: 7757314
    [Abstract] [Full Text] [Related]

  • 13. Effects of dihydropyridines and their combination with aspirin on blood pressure and circadian platelet activity in patients with essential hypertension.
    Tison P, Ulicna L, Jakubovska Z, Oravcova J, Fetkovska N.
    Am J Hypertens; 1994 Jul; 7(7 Pt 2):46S-49S. PubMed ID: 7946179
    [Abstract] [Full Text] [Related]

  • 14. Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin.
    Amstein R, Fetkovska N, Pletscher A, Bühler FR.
    J Hypertens; 1989 Apr; 7(4):255-60. PubMed ID: 2723427
    [Abstract] [Full Text] [Related]

  • 15. First clinical experience with isradipine in the treatment of hypertension in Portugal.
    Rocha-Gonçalves F, Mariano-Pego G, Viegas J, Correia JM, Botelho MA.
    J Cardiovasc Pharmacol; 1991 Apr; 18 Suppl 3():S4-6. PubMed ID: 1720485
    [Abstract] [Full Text] [Related]

  • 16. Effects of isradipine on hypertension and renal hemodynamics.
    Siamopoulos KC, Elisaf M, Dardamanis M, Sferopoulos G, Pappas M.
    J Cardiovasc Pharmacol; 1992 Apr; 19 Suppl 3():S87-9. PubMed ID: 1376846
    [Abstract] [Full Text] [Related]

  • 17. Platelet serotonin-LDL interaction in essential hypertension.
    Amstein R, Fetkovska N, Bühler FR.
    J Cardiovasc Pharmacol; 1991 Apr; 17 Suppl 5():S35-40. PubMed ID: 1717771
    [Abstract] [Full Text] [Related]

  • 18. Effects of ketanserin administration on lipid metabolism and platelet aggregation in hypertensive patients.
    Loschiavo C, Valvo E, Bedogna V, Casagrande P, Graziani MS, Nicoli M, Maschio G.
    Int J Clin Pharmacol Ther Toxicol; 1990 Nov; 28(11):455-7. PubMed ID: 2272704
    [Abstract] [Full Text] [Related]

  • 19. [In vivo platelet activation in mild arterial hypertension].
    Guicheney P, Baudouin-Legros M, Meyer P.
    Arch Mal Coeur Vaiss; 1987 Jun; 80(6):808-11. PubMed ID: 2959230
    [Abstract] [Full Text] [Related]

  • 20. Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group.
    Jern S, Hansson L, Scherstén B, Kullman S, Sörensen S, Dahlöf B, Eggertsen R, Sivertsson R.
    J Cardiovasc Pharmacol; 1991 Jun; 18 Suppl 3():S7-8. PubMed ID: 1720487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.